U.S. Stock Market Midday Update: Soligenix down 7.29%

U.S. Stock Market Midday Update

Soligenix fell 7.29%, with increased trading volume. Based on recent important news:

1. On August 6, Soligenix's financial report showed a net income of negative, with a basic earnings per share of -$0.77, leading to a 7.29% drop in stock price.

2. On August 5, Soligenix's product revenue fell short of expectations, raising market concerns about its future growth, further depressing the stock price.

3. On August 7, International Business Settlement's stock price rose 30.54%, attracting market attention and diverting investment interest away from Soligenix.

Stocks with High Trading Volume in the Industry

Gilead Sciences rose 9.01%, with a trading volume of $760 million. Based on recent important news:

1. On August 8, Gilead Sciences released its Q2 2025 financial report, showing a 2% year-over-year increase in total revenue to $7.1 billion, in line with market expectations, with a pre-market stock price increase of 2.9%.

2. On August 8, Gilead Sciences raised its full-year revenue and earnings guidance, expecting adjusted earnings per share to be between $7.95 and $8.25, higher than previously expected.

3. On August 9, Truist upgraded Gilead Sciences' rating from hold to buy and raised the target price from $108 to $127, with the stock price increasing by 8.3%.

Forty Pharmaceuticals fell 2.06%, with a trading volume of $652 million. Based on recent key news:

1. On August 8, Forty Pharmaceuticals' VX-993 failed to show significant pain relief effects in Phase II clinical trials, leading to an 18.8% drop in stock price.

2. On August 7, board member BRUCE SACHS made significant internal purchases, showing confidence in the company's future.

3. On August 6, analysts from RBC Capital and Scotiabank lowered the target price for Forty Pharmaceuticals, from $430 to $405 and from $442 to $438, respectively.

Natera rose 11.03%, with increased trading volume. Based on recent important news:

1. On August 8, Natera reported record quarterly revenue and raised its annual revenue and gross margin guidance, driving the stock price up by 11.03%.

2. On August 8, Natera's short interest ratio decreased by 41.44%, boosting market confidence in the company's prospects.

3. On August 8, multiple institutions raised Natera's target price, further enhancing market sentiment.

Stocks with High Market Capitalization in the Industry

AbbVie rose 0.10%, with increased trading volume. Based on recent important news:

1. On August 8, AbbVie raised its full-year guidance, with significant growth in Skyrizi in the psoriasis and IBD fields, boosting market confidence and increasing stock price

2. On August 6, AbbVie acquired Gilgamesh Pharmaceuticals to expand its market for mental disorder medications and enhance the company's competitiveness.

3. On August 5, AbbVie set a sales target of $24 billion, with no significant patent cliffs in the coming years, and market expectations are optimistic